Director, Global Center for Pathogen & Human Health Research
Department Chair, Cancer Biology
Director, Infection Biology
Betsy B. deWindt Endowed Chair in Cancer Biology
Location: Cleveland Clinic Main Campus
Dr. Jung’s cancer research focuses on virus-induced cancers, including Kaposi’s sarcoma, the most common tumor in patients with AIDS. For his work in this disease area, the National Cancer Institute awarded him the prestigious Outstanding Investigator Award in 2016.
Dr. Jung leads the Department of Cancer Biology and Global Center for Pathogen Research & Human Health, which is focused on broadening understanding of emerging pathogens.
Dr. Jung joined Cleveland Clinic from the University of Southern California, where he was chair of Molecular Microbiology and Immunology and director of the Institute of Emerging Pathogens and Immune Diseases. He earned his Ph.D. in microbiology from the University of California, Davis. He completed post-doctoral training and was later promoted to professor at Harvard Medical School. He is an elected fellow of the American Association for the Advancement of Science and the American Academy of Microbiology.
Fellowship - Harvard University
Cambridge, MA USA
Fellowship - Harvard Medical School
Boston, MA USA
Medical Education - University of California Davis Medical Center
Sacramento, CA USA
Graduate School - Seoul National University
Undergraduate - Seoul National University
Dr. Jung leads the Department of Cancer Biology and the newly-established Global Center for Pathogen Research & Human Health, which is focused on broadening understanding of emerging pathogens.
Dr. Jung has several research projects related to coronaviruses, including vaccine and drug development, and has developed one of the first preclinical models to study SARS-CoV-2 infection and transmission to lead to the development of a COVID-19 vaccine. His vaccine work utilizes nanoparticles that compel the coronavirus to use its own surface protein to produce antibodies that block viral infection. The hope is that this approach will have fewer side effects than other vaccines, especially among the older population that is particularly susceptible to COVID-19.
Dr. Jung and a multi-disciplinary team of scientists and clinicians in Ohio and Florida are collaborating to uncover the mechanisms of infectious agents and virus-induced cancers. He leads virology, immunology and oncology researchers working to make laboratory discoveries about how pathogens spread and cause disease and will collaborate with Cleveland Clinic’s Center for Therapeutics Discovery. He recently received a $2.8 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine for a newly emerging tick-borne disease.
View publications for Jae Jung, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Cleveland Clinic research into anti-viral immunity identified a novel mechanism in necroptosis, a form of programmed cell death
Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).
Cleveland Clinic researchers to participate in NIH consortium focused on antiviral drug development.
Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.
Dr. Jung’s team studied blood samples collected from mothers with COVID-19 and their infant children who were exposed to SARS-CoV-2 to understand how infection modulates the expression of different inflammatory molecules.
Dr. Jung's endowed chair will support his research into infectious diseases and virus-induced cancers.
Dr. Jung and his team have developed a vaccine candidate that targets the primary binding site between SARS-Cov-2 and human cells, which universally produced neutralizing antibodies and prevented infection in preclinical models.
Using patient samples, Dr. Jung and his team uncovered inflammatory biomarkers associated with severe disease and death caused by SFTSV infection, and identified the critical role B cells play in infection.
Dr. Jung and his team defined the molecular mechanisms that underlie fetal brain calcification caused by Zika virus infection, most notably identifying the role of the protease NS3 in driving the virus-induced abnormal brain development.
Through a $500 million partnership with the State of Ohio, JobsOhio and Ohio Development Services Agency, Cleveland Clinic will strengthen and grow its commitment to infectious disease research as the new Center will support research, education and grow new jobs in Ohio.